Nowe formy rehabilitacji neurologopedycznej jako odpowiedź na nowe formy farmakoterapii w chorobie Alzheimera

• Authors: Ewa Wolańska

Title variants

EN

New forms of speech-language pathology therapy as a response to new forms of pharmacotherapy in Alzheimer’s disease

Abstracts

EN

Alzheimer’s disease (AD) is one of neurodegenerative diseases causing progressive and irreversible loss of neurons in various regions of the brain. It is characterised by memory deficits and disorders such as aphasia, apraxia, and agnosia. Cognitive impairment results in deteriorated functioning of the patient with respect to the initial condition to the extent debilitating their everyday functioning. The paper presents the initial results of the research on new types of medications used to treat AD. If, after completing clinical trials, it proves that the new substances stop or significantly slow the progression of neurodegeneration, physical therapists or various specialties, including speech-language pathologists, will deal with a completely new task. This is because in the face of an extremely difficult therapeutic situation, resulting from unfavourable prognosis in AD, the patient’s frequent demotivation, etc., they have endeavoured only to stabilise the patient’s cognitive functions and communication capabilities to this date. Now in turn the therapy’s aim will be to enable the patient to regain a relative independence through stimulation of the natural reconstruction of the damaged functions and teaching the patient how to compensate for the deficits which prove permanent.

• Publisher: Towarzystwo Kultury Języka
• Journal: Poradnik Językowy
• Year: 2017
• Volume: 745
• Issue: 6
• Pages: 39-52

Dates

published

2017

Contributors

author

Ewa Wolańska

• Uniwersytet Warszawski

References

• R. Alexander i in., 2014, AZD3293. A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF Aβ peptides following single-and multiple--dose administration, „Neurobiology of Aging” 35, s. S2.
• E. Arnáiz, O. Almkvist, 2003, Neuropsychological features of mild cognitive impairment and preclinical Alzheimer’s disease, „Acta Neurologica Scandinavica. Supplementum” 179, s. 34–41.
• P. Bąbel, A. Baran, 2011, Trening pamięci, Warszawa.
• L. Bäckman i in., 2004, Multiple cognitive deficits during the transition to Alzheimer’s disease, „Journal of Internal Medicine” 256(3), s. 195–204.
• F. Bermejo-Pareja i in., 2008, Incidence and subtypes of dementia in three elderly populations of central Spain, „Journal of the Neurological Sciences” 264(1–2), s. 63–72.
• A. Bilikiewicz i in., 2003, Psychiatria, t. III, Wrocław.
• D.R. Borchelt i in., 1996, Familial Alzheimer’s disease-linked presenilin 1 variants elevate βA1-42/1-40 ratio in vitro and in vivo, „Neuron” 17(5), s. 1005–1013.
• W. Chun, G.V. Johnson, 2007, The role of tau phosphorylation and cleavage in neuronal cell death, „Frontiers in Bioscience” 12, s. 733–56.
• R.S. Desikan i in., 2009, Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer’s disease, „Brain” 132(8), s. 2048–2057.
• A. Di Carlo i in., 2002, Alzheimer’s disease, and vascular dementia in Italy. The ILSA Study, „Journal of the American Geriatrics Society” 50(1), s. 41–48.
• Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR, 2000, Arlington.
• A. Domagała, 2000, Standard postępowania logopedycznego w przypadku zaburzeń mowy w otępieniu alzheimerowskim, „Logopedia” t. XXXVII, s. 297–311.
• A. Domagała, 2007, Zachowania językowe w demencji, Lublin.
• S. Eketjäll i in., 2016, AZD3293: A novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics, „Journal of Alzheimer’s Disease” 50(4), s. 1109–1123.
• P.S. Eriksson i in., 1998, Neurogenesis in the adult human hippocampus, „Nature Medicine” 4(11), s. 1313–1317.
• M. Forman i in., 2013, The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer’s disease, „Alzheimer’s & Dementia” 9(4), s. 139.
• H. Förstl, A. Kurz, 1999, Clinical features of Alzheimer’s disease, „European Archives of Psychiatry and Clinical Neuroscience” 249(6), s. 288–290.
• P.T. Francis i in., 1999, The cholinergic hypothesis of Alzheimer’s disease: a review of progress, „The Journal of Neurology, Neurosurgery, and Psychiatry” 66(2), s. 137–147.
• E.M. Frank, 1994, Effect of Alzheimer’s disease on communication function, „Journal of the South Carolina Medical Association” 90(9), s. 417–423.
• B. Frost i in., 2003, Reorganization of remote cortical regions after ischemic brain injury: a potential substrate for stroke recovery, „The Journal of Neurophysiology” 89(6), s. 3205–3214.
• M. Goedert, M.G. Spillantini, R.A. Crowther, 1991, Tau proteins and neurofi brillary degeneration, „Brain Pathology” 1(4), s. 279–286.
• S.B. Haeberlein i in., 2013, AZD3293, a potent and selective orally active, brain-permeable BACE1 inhibitor, „Alzheimer’s & Dementia” 9(4), s. P813.
• J. Hardy, D. Allsop, 1991, Amyloid deposition as the central event in the aetiology of Alzheimer’s disease, „Trends in Pharmacological Sciences” 12(10), s. 383–388.
• K. Höglund i in., 2014, Monitoring the Soluble Amyloid Precursor Protein Alpha (SAPPA) and Beta (SAPPB) fragments in plasma and CSF from healthy individuals treated with bace inhibitor AZD3293 in a multiple ascending dose study: Pharmacokinetic and Pharmacodynamic correlate, „Alzheimer’s & Dementia” 10(4), s. P447.
• K. Iqbal i in., 2005, Tau pathology in Alzheimer disease and other tauopathies, „Biochimica et Biophysica Acta” 1739(2–3), s. 198–210.
• K. Jodzio, W.M. Nyka, 2008, Zaburzenia językowe oraz mowy w praktyce ogólnolekarskiej, „Forum Medycyny Rodzinnej” nr 2, s. 14–22.
• D. Kądzielawa, 2008, Rehabilitacja osób z uszkodzeniami lewostronnymi mózgu [w:] E. Łojek, A. Bolewska (red.), Wybrane zagadnienia rehabilitacji neuropsychologicznej, Warszawa, s. 56–71.
• G. Kempermann, D. Gast, F.H. Gage, 2002, Neuroplasticity in old age: sustained fivefold induction of hippocampal neurogenesis by long-term environmental enrichment, „Annals of Neurology” 52(2), s. 135–143.
• K. Kot-Bryćko, F. Pietraszkiewicz, 2012, Psychologia w medycynie. Część 2 – rehabilitacja neuropsychologiczna po udarze mózgu, „Medycyna Ogólna i Nauki o Zdrowiu” nr 4, s. 344–347.
• Y.F. Liu i in., 2009, Differential effects of treadmill running and wheel running on spatial or aversive learning and memory: roles of amygdalar brain-derived neurotrophic factor and synaptotagmin I, „The Journal of Physiology” 587(13), s. 3221–3231.
• E. Łojek, 2008, Rehabilitacja neuropsychologiczna osób z uszkodzeniami prawej półkuli mózgu [w:] E. Łojek, A. Bolewska (red.), Wybrane zagadnienia rehabilitacji neuropsychologicznej, Warszawa, s. 72–95.
• H. Marczewska, E. Osiejuk, 1994, Nie tylko afazja... O zaburzeniach w demencji Alzheimera, demencji wielozawałowej i przy uszkodzeniach prawej półkuli mózgu, Warszawa.
• M. Merzenich i in., 1983, Topographic reorganization of somatosensory cortical areas 3b and 1 in adult monkeys following restricted deafferentation, „Neuroscience” 8, s. 33–55.
• R. Moan, 2009, MRI software accurately IDs preclinical Alzheimer’s disease, „Diagnostic Imaging” July 20.
• J. Mroziak, 2008, Rehabilitacja neuropsychologiczna osób z zaburzeniami pamięci [w:] E. Łojek, A. Bolewska (red.), Wybrane zagadnienia rehabilitacji neuropsychologicznej, Warszawa, s. 96–122.
• A. Mudher, S. Lovestone, 2002, Alzheimer’s disease-do tauists and baptists finally shake hands?, „Trends in Neurosciences” 25(1), s. 22–26.
• A. Nikolaev i in., 2009, APP binds DR6 to cause axon pruning and neuron death via distinct caspases, „Nature” 457(7232), s. 981–989.
• P. Nocoń, 2009, Zaburzenia komunikacji w zespołach otępiennych, „MEDI – Forum Opieki Długoterminowej” nr 2, s. 15–18.
• M. Pąchalska, 2009, Rehabilitacja neuropsychologiczna, Lublin.
• J. Panasiuk, 2015, Postępowanie logopedyczne w przypadkach chorób neurodegeneracyjnych [w:] S. Grabias, J. Panasiuk, T. Woźniak (red.), Logopedia. Standardy postępowania logopedycznego. Podręcznik akademicki, Lublin, s. 955–992.
• T. Polvikoski i in., 1995, Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein, „The New England Journal of Medicine” 333(19), s. 1242–1247.
• S. Ramon y Cajal, 1928, Degeneration and Regeneration of the Nervous System, London.
• J. Sevigny i in., 2015, Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer’s disease: Interim results of a randomized, double-blind, placebo-controlled, phase 1b study, „Alzheimer’s & Dementia” 11(7), s. P277.
• J. Sevigny i in., 2016, The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease, „Nature” 537, s. 50–56.
• Z.X. Shen, 2004, Brain cholinesterases: II. The molecular and cellular basis of Alzheimer’s disease, „Medical Hypotheses” 63(2), s. 308–321.
• E.M. Szepietowska, B. Daniluk, 2000, Zaburzenia językowe w demencji w ujęciu neuropsychologii klinicznej [w:] Audiofonologia t. XVI, Lublin, s. 117–135.
• V. Taler, N.A. Phillips, 2008, Language performance in Alzheimer’s disease and mild cognitive impairment: a comparative review, „Journal of Clinical and Experimental Neuropsychology” 30(5), s. 501–556.
• G. Waldemar i in., 2007, Recommendations for the diagnosis and management of Alzheimer;s disease and other disorders associated with dementia: EFNS guideline, „European Journal of Neurology” 14(1), s. 1–26.
• G.L. Wenk, 2003, Neuropathologic changes in Alzheimer’s disease, „The Journal of Clinical Psychiatry” 64 (supl. 9), s. 7–10.
• R. Yan, R. Vassar, 2014, Targeting the β secretase BACE1 for Alzheimer’s disease therapy, „The Lancet Neurology” 13(3), s. 319–329.

Identifiers

Biblioteka Nauki

3152329